Home » Stocks » VistaGen Therapeutics

VistaGen Therapeutics, Inc. (VTGN)

Stock Price: $0.810 USD 0.000 (0.00%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
After-hours: $0.800 -0.010 (-1.21%) Aug 4, 7:57 PM

Stock Price Chart

Key Info

Market Cap 45.49M
Revenue (ttm) n/a
Net Income (ttm) -20.77M
Shares Out 56.03M
EPS (ttm) -0.50
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $0.810
Previous Close $0.810
Change ($) 0.000
Change (%) 0.00%
Day's Open 0.800
Day's Range 0.781 - 0.830
Day's Volume 4,761,271
52-Week Range 0.294 - 1.490

More Stats

Market Cap 45.49M
Enterprise Value 48.23M
Earnings Date (est) Aug 18, 2020
Ex-Dividend Date n/a
Shares Outstanding 56.03M
Float 46.88M
EPS (basic) -0.5
EPS (diluted) -0.50
FCF / Share -0.33
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.79M
Short Ratio 1.34
Short % of Float 2.87%
Beta 0.12
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 26.54
Revenue n/a
Operating Income -20.80M
Net Income -20.77M
Free Cash Flow -15.76M
Net Cash -2.74M
Net Cash / Share -0.05
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -131.43%
ROE -411.13%
ROIC -378.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$3.00*
Low
3.00
Current: $0.810
High
3.00
Target: 3.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue---1.25---0.201.342.07
Revenue Growth--------85.07%-35.19%-
Gross Profit---1.25---0.201.342.07
Operating Income-20.80-24.56-14.20-10.25-17.85-6.78-5.03-6.79-9.04-6.56
Net Income-20.77-24.59-14.35-10.26-47.22-13.89-2.97-12.89-12.21-9.48
Shares Outstanding47.9628.5613.897.531.771.471.170.910.74-
Earnings Per Share-0.50-0.90-1.12-1.54-29.08-10.61-3.81-25.40-16.60-36.20
Operating Cash Flow-15.76-14.53-9.06-7.26-4.81-2.77-2.13-3.46-3.57-0.84
Capital Expenditures--0.17--0.24-0.03--0.01-0.14-0.03-0.06
Free Cash Flow-15.76-14.70-9.06-7.50-4.83-2.77-2.14-3.60-3.60-0.90
Cash & Equivalents1.3613.1010.382.920.430.070.000.640.080.14
Total Debt4.090.070.070.070.0714.266.925.353.5711.80
Net Cash / Debt-2.7413.0310.312.850.36-14.19-6.92-4.71-3.49-11.66
Assets5.7714.0111.283.710.990.270.260.880.340.32
Liabilities11.506.944.363.103.9720.8113.0613.446.0518.67
Book Value-5.737.086.920.62-2.98-20.54-12.80-12.56-5.71-32.88
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name VistaGen Therapeutics, Inc.
Country United States
Employees 9
CEO Shawn K. Singh

Stock Information

Ticker Symbol VTGN
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: VTGN

Description

VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines to treat diseases and disorders of the central nervous system. It focuses on depressive and social anxiety disorders. The company's lead product candidate is AV-101 that is in Phase II clinical trial for the treatment of chronic neuropathic pain, epilepsy, major depressive disorder (MDD), parkinson's disease levodopa-induced dyskinesia, and suicidal ideation; PH94B, a neuroactive nasal spray that is in Phase III clinical trial for social anxiety disorder (SAD), and Phase IIa clinical trial for generalized anxiety disorder; and PH10, a neuroactive nasal spray that is in Phase IIb clinical trial for MDD. It has licensing, sublicensing, and collaboration agreements with Pherin Pharmaceuticals, Inc.; BlueRock Therapeutics, LP; and Cato Research Ltd. The company also has a strategic licensing and collaboration agreement with EverInsight Therapeutics Inc. for the clinical development and commercialization of PH94B for multiple anxiety-related disorders in Greater China, South Korea, and Southeast Asia. VistaGen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.